Trial Profile
A trial to develop a multi-analyte serum panel of specific proteins with predictive value for erlotinib versus palliative chemotherapy in pretreated advanced NSCLC patients that were unselected for EGFR mutation status
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2015
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- 23 Dec 2015 New trial record